Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting an...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-964-5442
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
DIJG
DIJG Aug. 28 at 4:58 PM
$MDNAF MDNA’s tape tells the story: those repeated 500‑share prints aren’t humans, they’re algorithms doing what they do best. A tiny 500‑share sell can drag the price down, yet a 9,000‑share buy barely moves it — classic microcap order‑book imbalance. Fortunately, the science isn’t nearly as unstable as the stock price. One day, the price will have no choice but to catch up to the data.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 28 at 2:46 PM
$MDNAF can we get .50 CNTS to close the week??
1 · Reply
DIJG
DIJG Aug. 26 at 3:12 PM
$MDNAF Early 2024, MDNA11 got an ASCO oral presentation — a rarity for a Phase 1 with only ~20 patients, since ASCO & others typically reserves oral slots for Phase 2 or 3. 13 May 2024, ASCO withdrew the abstract due to its prior publication policy, not failure of science. The reputational damage, however, was immediate. Coming just months after its NASDAQ delisting, the reversal felt like a second blow. With the oral slot gone, Medicenna presented the data it described as groundbreaking through a random virtual event — a format that inevitably muted the impact deserving for a such result. 2yrs later, MDNA11 has re-emerged with more mature data, earning yet another oral presentation — a powerful form of external validation. Committees do not grant oral sessions based on hypothetical or previously released results, so you can draw your own conclusions about what this implies for upcoming readout. Institutions will be watching and hopefully MDNA11 can get the shine it truely deserves
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 26 at 2:16 PM
Wake up $XLO . Neoadjuvant is the setting to start. $AGEN got this right $MDNAF getting there too
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 25 at 8:31 PM
$MDNAF David (Substack) isn’t promoting any AI models, he is laser focused on Medicenna. “PRISM” is his MDNA11/55/113 AI analysis tool, he tailored an algorithm to focus on IO research and how past/current developments reflect positively or negatively on what Medicenna is trying to accomplish. If you are comfortable with AI platforms you can easily do it yourself, but there is a lot of training, time and proofing required to get it right David/Prism gets it right!
2 · Reply
_Osmium
_Osmium Aug. 25 at 4:36 PM
$MDNAF Here's what I see: A couple new super bullish posters. David (from Substack) is once more putting out copious amounts of analysis. The stock itself is still skipping along the bottom and may or may not have formed one. Holding since 2018, I can tell you that we need to see that enormous volume day before this stock changes its nature. A muted response to the ABILITY study and it's over for Medicenna. With a strong positive outcome expect either an instant raise of capital or some form of partnership to alleviate another highly dilutive raise. Alternatively, an outright acquisition is possible, but I'm not going that far based on my tenure with the stock. In short, serious money (think $20 million plus) will be needed early next year, to run much larger trials. Finally, to anyone new, David is bright and very convincing but be careful; he's promoting his PRISM AI model and right or wrong chose Medicenna to hilight its capabilities. This is an all or nothing investment.
4 · Reply
DIJG
DIJG Aug. 25 at 1:58 PM
$MDNAF PD-1 refactory (i.e no response to PD-1 drugs like Keytruda, Nivo) are the hardest tumor to treat in Oncology. Since 2018, You cannot ethically or legally start a new immunotherapy trial in an easy population (PD-1 Naïve) where PD 1 already works. So MDNA11 didn’t start in the hardest tumors by choice — it started there because modern immunotherapy trials require it. Other IL‑2s with mega billion$ deals (Nektar, Synthrox, Alkermes, Xilio, etc) started in the same place, failed, and quickly retreated to easier tumors — and still failed. MDNA11 is the first IL‑2 showing real activity in PD‑1–refractory disease, proving that when the biology is solid, a drug can win in the toughest cancers first. If a drug works in PD 1–refractory tumors, it’s almost guaranteed to work in easier tumors. So, starting in the hardest setting is actually: A stress test. If the drug passes, it’s a monster. MDNA11 is passing! - The upcoming oral presentation shows the science is holding up very well
1 · Reply
ewll
ewll Aug. 24 at 10:04 PM
$MDNAF have you question why mdna113 IND filling is a little delayed?
1 · Reply
ewll
ewll Aug. 24 at 9:28 PM
$MDNAF The NEO-CYT trial could be a major value driver for Medicenna (MDNA) as it evaluates MDNA11 in first-line, neoadjuvant Stage III melanoma, expanding development from late-stage refractory disease into a larger, earlier-stage setting with curative intent. The study is led by Professor Paolo Ascierto, a world-renowned melanoma expert recently recognized by SITC, and sponsored by Fondazione Melanoma Onlus, reflecting strong confidence in MDNA11's potential. Importantly, the foundation is funding and sponsoring the trial while Medicenna supplies the drug, enabling MDNA to generate valuable frontline data without bearing the full $20M+ cost of a randomized multicenter study.
2 · Reply
DIJG
DIJG Aug. 24 at 7:56 PM
$MDNAF PD-1 therapy like Keytruda came to the market in 2014. PD-1 resistance which existed today never existed when Keytruda & co were undergoing their clinical trials. Keytruda trial used PD-1 naive patients.PD-1 refactory only became known bcos they were created by Keytruda & co. So MDNA11 showing: PRs, deep shrinkage, durable responses in PD 1–refractory tumors is far more impressive than Keytruda’s early results in PD 1–naïve tumors.
0 · Reply
Latest News on MDNAF
No data available.
DIJG
DIJG Aug. 28 at 4:58 PM
$MDNAF MDNA’s tape tells the story: those repeated 500‑share prints aren’t humans, they’re algorithms doing what they do best. A tiny 500‑share sell can drag the price down, yet a 9,000‑share buy barely moves it — classic microcap order‑book imbalance. Fortunately, the science isn’t nearly as unstable as the stock price. One day, the price will have no choice but to catch up to the data.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 28 at 2:46 PM
$MDNAF can we get .50 CNTS to close the week??
1 · Reply
DIJG
DIJG Aug. 26 at 3:12 PM
$MDNAF Early 2024, MDNA11 got an ASCO oral presentation — a rarity for a Phase 1 with only ~20 patients, since ASCO & others typically reserves oral slots for Phase 2 or 3. 13 May 2024, ASCO withdrew the abstract due to its prior publication policy, not failure of science. The reputational damage, however, was immediate. Coming just months after its NASDAQ delisting, the reversal felt like a second blow. With the oral slot gone, Medicenna presented the data it described as groundbreaking through a random virtual event — a format that inevitably muted the impact deserving for a such result. 2yrs later, MDNA11 has re-emerged with more mature data, earning yet another oral presentation — a powerful form of external validation. Committees do not grant oral sessions based on hypothetical or previously released results, so you can draw your own conclusions about what this implies for upcoming readout. Institutions will be watching and hopefully MDNA11 can get the shine it truely deserves
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 26 at 2:16 PM
Wake up $XLO . Neoadjuvant is the setting to start. $AGEN got this right $MDNAF getting there too
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 25 at 8:31 PM
$MDNAF David (Substack) isn’t promoting any AI models, he is laser focused on Medicenna. “PRISM” is his MDNA11/55/113 AI analysis tool, he tailored an algorithm to focus on IO research and how past/current developments reflect positively or negatively on what Medicenna is trying to accomplish. If you are comfortable with AI platforms you can easily do it yourself, but there is a lot of training, time and proofing required to get it right David/Prism gets it right!
2 · Reply
_Osmium
_Osmium Aug. 25 at 4:36 PM
$MDNAF Here's what I see: A couple new super bullish posters. David (from Substack) is once more putting out copious amounts of analysis. The stock itself is still skipping along the bottom and may or may not have formed one. Holding since 2018, I can tell you that we need to see that enormous volume day before this stock changes its nature. A muted response to the ABILITY study and it's over for Medicenna. With a strong positive outcome expect either an instant raise of capital or some form of partnership to alleviate another highly dilutive raise. Alternatively, an outright acquisition is possible, but I'm not going that far based on my tenure with the stock. In short, serious money (think $20 million plus) will be needed early next year, to run much larger trials. Finally, to anyone new, David is bright and very convincing but be careful; he's promoting his PRISM AI model and right or wrong chose Medicenna to hilight its capabilities. This is an all or nothing investment.
4 · Reply
DIJG
DIJG Aug. 25 at 1:58 PM
$MDNAF PD-1 refactory (i.e no response to PD-1 drugs like Keytruda, Nivo) are the hardest tumor to treat in Oncology. Since 2018, You cannot ethically or legally start a new immunotherapy trial in an easy population (PD-1 Naïve) where PD 1 already works. So MDNA11 didn’t start in the hardest tumors by choice — it started there because modern immunotherapy trials require it. Other IL‑2s with mega billion$ deals (Nektar, Synthrox, Alkermes, Xilio, etc) started in the same place, failed, and quickly retreated to easier tumors — and still failed. MDNA11 is the first IL‑2 showing real activity in PD‑1–refractory disease, proving that when the biology is solid, a drug can win in the toughest cancers first. If a drug works in PD 1–refractory tumors, it’s almost guaranteed to work in easier tumors. So, starting in the hardest setting is actually: A stress test. If the drug passes, it’s a monster. MDNA11 is passing! - The upcoming oral presentation shows the science is holding up very well
1 · Reply
ewll
ewll Aug. 24 at 10:04 PM
$MDNAF have you question why mdna113 IND filling is a little delayed?
1 · Reply
ewll
ewll Aug. 24 at 9:28 PM
$MDNAF The NEO-CYT trial could be a major value driver for Medicenna (MDNA) as it evaluates MDNA11 in first-line, neoadjuvant Stage III melanoma, expanding development from late-stage refractory disease into a larger, earlier-stage setting with curative intent. The study is led by Professor Paolo Ascierto, a world-renowned melanoma expert recently recognized by SITC, and sponsored by Fondazione Melanoma Onlus, reflecting strong confidence in MDNA11's potential. Importantly, the foundation is funding and sponsoring the trial while Medicenna supplies the drug, enabling MDNA to generate valuable frontline data without bearing the full $20M+ cost of a randomized multicenter study.
2 · Reply
DIJG
DIJG Aug. 24 at 7:56 PM
$MDNAF PD-1 therapy like Keytruda came to the market in 2014. PD-1 resistance which existed today never existed when Keytruda & co were undergoing their clinical trials. Keytruda trial used PD-1 naive patients.PD-1 refactory only became known bcos they were created by Keytruda & co. So MDNA11 showing: PRs, deep shrinkage, durable responses in PD 1–refractory tumors is far more impressive than Keytruda’s early results in PD 1–naïve tumors.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 24 at 6:57 PM
$MDNAF
0 · Reply
ewll
ewll Aug. 21 at 1:29 PM
$MDNAF $HOWL is gone. Enhanced beta and none alpha is the way for IL-2 drug moving forward.
2 · Reply
DIJG
DIJG Aug. 20 at 4:46 PM
$MDNAF Not every Keytruda combo on ClinicalTrials.gov gets a KEYNOTE number. Merck only tags a trial with a KEYNOTE identifier when it’s part of their internal Keytruda development ecosystem — meaning Merck is actively tracking, reviewing, and aligning the study with their own strategic plans. For ABILITY‑1 (NCT05086692), the identifiers tell the story: MDNA11‑01, KEYNOTE‑E53 (Merck identifier), MK3475‑E53 (Merck identifier) That KEYNOTE‑E53 tag is not random. It means Merck has pulled the MDNA11 + Keytruda combo into their internal pipeline tracking. This is a level of involvement far beyond a simple drug‑supply agreement. On top of that, Medicenna and Merck have a Joint Development Committee (JDC). A JDC is a big deal — it means Merck is:co‑reviewing MDNA11 combo data involved in tumor‑type prioritization contributing to biomarker strategy providing input on protocol development ........ Continue below
2 · Reply
BULLISH1975
BULLISH1975 Aug. 19 at 4:12 PM
$ICU most sheep/retail have zero patience! They look at low SP, cry and sell. they chase flavor of week!!! SCD device works- SAVE registry and red tape slowed adoption!!!! so many ped patients are/ have been saved!!! FdA SAVE news in coming weeks- huge catalyst FDA SAVE being dropped is not just a catalyst/— its going to increase costumers, revenue, exposure and give the SCD an FDA blessing- tick of approval! float 4 million shares!! adult phase III trial progressing $ENSC $GME $MDNAF dyor
0 · Reply
ewll
ewll Aug. 19 at 3:48 PM
$MDNAF Moderna’s personalized mRNA vaccine (mRNA-4157) is administered in the adjuvant setting following surgical resection. In contrast, the NEO-CYT trial evaluates MDNA11 combinations in the neoadjuvant setting for resectable stage III melanoma. By comparison, KEYNOTE-942 demonstrated a recurrence-free survival HR of 0.51 for adjuvant mRNA plus pembrolizumab, whereas the benchmark NADINA trial showed an event-free survival HR of 0.32 with neoadjuvant ipilimumab plus nivolumab. Consequently, neoadjuvant immunotherapy presents a more compelling risk reduction than standard adjuvant approaches.
0 · Reply
DIJG
DIJG Aug. 19 at 2:40 PM
$MDNAF Interesting to note that MDNA55 never received an oral presentation during its active clinical trial years (2017–2020). The highest it ever reached were poster sessions. rGBM is a graveyard for drugs: Novocure TTF failed, DCVax stalled, oncolytic viruses collapsed, checkpoint inhibitors, CAR‑T, NK cell therapies, small molecules — all failed in rapid succession. Even blockbuster Keytruda and Opdivo couldn’t move the needle. Merck had to abandon its rGBM program. So MDNA55 now being elevated to an oral session is a genuinely big deal. It signals renewed scientific interest in a field desperate for something that actually works. MDNA55 is no doubt in the top tier — one of the strongest and safest rGBM therapies ever tested. Even analysts consistently discount MDNA55 and they dont include it in any Medicenna's forecast. This oral session might be the spark MDNA55 needs to finally get the attention it truly deserves. It’s only a matter of time.
0 · Reply
DIJG
DIJG Aug. 19 at 1:55 PM
$MDNAF Huge news out today from Merck/Moderna. Cancer vaccine is great news for patient. It is important to note that the cancer vaccine is for neo-adjuvent setting while MDNA11 is in Advanced/Metastatic disease setting both drugs are not competing
1 · Reply
rudazur2
rudazur2 Aug. 19 at 11:22 AM
$MDNAF bad news for us with moderna and merck succes in ph3
2 · Reply
Lytnup
Lytnup Aug. 18 at 4:16 AM
$MDNAF And another one https://substack.com/@david132748/note/p-211573009?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://substack.com/@david132748/note/p-211576131?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 17 at 2:07 AM
$MDNAF
0 · Reply
steven1x
steven1x Aug. 16 at 6:20 PM
$MDNAF timeframe? https://g.co/gemini/share/336ed2250bb0
0 · Reply
Lytnup
Lytnup Aug. 14 at 9:51 PM
$MDNAF In case anyone else besides me doesn’t have anything better to do, I would recommend David’s latest Investment Summary (over an hour and a half, with lots of information), along with the updated August 2026 Slide Deck (which shows Dr. Ascierto as Chair of MDNAs Clinical Advisory Board, and Dr. Ibrahim as CMO - no longer fractional?) https://substack.com/@david132748/note/p-211080994?r=10wt7d&utm_medium=ios&utm_source=notes-share-action https://ir.medicenna.com/static-files/f4748b19-5500-4d9e-b2d4-0c08830b627c
1 · Reply